Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in VXL?
Vaxil: THE INVESTMENT CASE

Vaxil at the vanguard of immuno-oncology

The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
Vaxil at the vanguard of immuno-oncology
INVESTMENT OVERVIEW: VXL The Big Picture
Vaxil in the spotlight with good investment prospects

Immuno-oncology is a type of cancer treatment designed to boost the body's natural defences to fight the disease.

It uses substances either made by the body or in a laboratory to improve or restore immune system function.

Immunotherapy in cancer treatment could every bit as significant as the breakthroughs made in HIV/AIDS and Hepatitis around 15 years ago, according to the specialist research firm BioNap.

“For biotech investors, the prospect of curing cancer has led to an abundance of opportunities as more and more companies enter the space,” it said in a note published this week.

Interest in this emerging area is such that an exchange-traded fund dedicated to cancer immunotherapy has been set up that invests in a spread of companies in this sector.

It is called the Series Solutions Trust Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR).

One company at the vanguard of immuno-oncology is Ontario-based Vaxil Bio Ltd (CVE:VXL).

Read Vaxil gets US Patent and Trademark nod for Immunotherapy tech

It is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

In fact, MUC1 antigen is a well-known cancer marker present in 90% of all cancers.

ImMucin was recently shown to work in combination with leading checkpoint inhibitors, such as anti-PD1 and anti-CTLA-4 antibodies, inhibiting the spread of tumours in bone marrow and blood samples derived from multiple myeloma patients.

Combination therapies of this kind are increasingly seen as the way ahead given the complexities associated with the disease and the diverse responses humans have to the current crop of drugs.

Vaxil features in new research report

Vaxil has just been featured as a stock to watch in a research note from BioNap.

“ImMucin, and its derived antibodies could ultimately serve as starting materials for the development of specific T cell therapies such as CAR-T and allogeneic T cell transplantation,” said BioNap.

 “Since the safety of ImMucin has proven excellent and it has the capacity to work across immunologic barriers, it appears to be a natural candidate to combine with these modalities and others.”

Those, like Vaxil, exploring immunotherapy cancer combat may also be recipients of financial aid from the $1.8bn earmarked for outgoing President Barack Obama’s national “Moonshot” initiative to eliminate cancer, unveiled at the last State of the Union speech in January 2016.

Read Vaxil Bio encouraged by cancer drug progress on two fronts

Vaxil’s drug, meanwhile, has received Orphan Drug Designation in the US and Europe and completed a successful Phase-I/II trial.

This should shorten the time it takes to get the treatment out onto the market if it successfully navigates the R&D phase.

The company has also branched outside of North America, to work with other leading institutions around the world.

Read Vaxil collaborates with Israel’s Hadassah Medical Center

 

View full VXL profile View Profile

Vaxil Timeline

Related Articles

picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
cancer cells
July 12 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use